{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:23:59Z","timestamp":1788456239090,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"am","delay-in-days":281,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016255","name":"INOVIO Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016255","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009655","name":"Sunovion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014387","name":"ACADIA Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014387","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015303","name":"Otsuka Pharmaceutical Development and Commercialization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015303","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001039","name":"Cleveland Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001039","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002975","name":"Dainippon Sumitomo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["1R01HS019371"],"award-info":[{"award-number":["1R01HS019371"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016939","name":"Myriad Genetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016939","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021138","name":"Lundbeck Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021138","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001455","name":"American Foundation for Suicide Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001455","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.jad.2019.06.050","type":"journal-article","created":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T22:46:05Z","timestamp":1562021165000},"page":"17-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Complex polypharmacy in bipolar disorder: Side effect burden, adherence, and response predictors"],"prefix":"10.1016","volume":"257","author":[{"given":"Vicki C.","family":"Fung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay N.","family":"Overhage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa G.","family":"Sylvia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noreen A.","family":"Reilly-Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Kamali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keming","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard C.","family":"Shelton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence A.","family":"Ketter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William V.","family":"Bobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Thase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Tohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thilo","family":"Deckersbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Nierenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jad.2019.06.050_bib0001","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1034\/j.1600-0447.2000.90061.x","article-title":"Predicting medication adherence in severe mental disorders","volume":"101","author":"Adams","year":"2000","journal-title":"Acta Psychiatr. Scand."},{"issue":"10","key":"10.1016\/j.jad.2019.06.050_bib0002","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1176\/ps.2008.59.10.1175","article-title":"Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence","volume":"59","author":"Baldessarini","year":"2008","journal-title":"Psychiatr. Serv."},{"issue":"9","key":"10.1016\/j.jad.2019.06.050_bib0003","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s40263-018-0542-4","article-title":"Association between psychotropic medication polypharmacy and an objective measure of balance impairment among middle-aged adults: results from the US National Health and Nutrition Examination Survey","volume":"32","author":"Bareis","year":"2018","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.jad.2019.06.050_bib0004","first-page":"e1","article-title":"Correlates of medication adherence among patients with bipolar disorder: results of the bipolar evaluation of satisfaction and tolerability (BEST) study: a nationwide cross-sectional survey","volume":"12","author":"Bates","year":"2010","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2019.06.050_bib0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jad.2014.02.046","article-title":"Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: results from the bipolar CHOICE trial","volume":"161","author":"Bobo","year":"2014","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2019.06.050_bib0006","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00004850-199905030-00010","article-title":"Extrapyramidal symptoms associated with the adjunct of nortriptyline to a venlafaxine-valproic acid combination","volume":"14","author":"Conforti","year":"1998","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.jad.2019.06.050_bib0007","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11920-018-0881-3","article-title":"Possible pharmacodynamic and pharmacokinetic drug-drug interactions that are likely to be clinically relevant and\/or frequent in bipolar disorder","volume":"20","author":"de Leon","year":"2018","journal-title":"Curr. Psychiatry Rep."},{"issue":"9","key":"10.1016\/j.jad.2019.06.050_bib0008","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s40263-015-0275-6","article-title":"Diagnosis, epidemiology and management of mixed states in bipolar disorder","volume":"29","author":"Fagiolini","year":"2015","journal-title":"CNS Drugs"},{"issue":"7","key":"10.1016\/j.jad.2019.06.050_bib0009","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/MLR.0b013e31829019c5","article-title":"Adverse clinical events among medicare beneficiaries using antipsychotic drugs","volume":"51","author":"Fung","year":"2013","journal-title":"Med. Care"},{"issue":"1","key":"10.1016\/j.jad.2019.06.050_bib0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/104012370902100102","article-title":"Association between antipsychotic combination therapy and treatment adherence among individuals with bipolar disorder","volume":"21","author":"Gianfrancesco","year":"2009","journal-title":"Ann. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2019.06.050_bib0011","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1176\/appi.ajp.2008.08050746","article-title":"Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP-BD","volume":"166","author":"Goldberg","year":"2009","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2019.06.050_bib0012","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jad.2017.06.005","article-title":"Complex psychotropic polypharmacy in bipolar disorder across varying mood polarities: a prospective cohort study of 2712 inpatients","volume":"221","author":"Golden","year":"2017","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2019.06.050_bib0013","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2147\/NDT.S166730","article-title":"Systematic literature review on patterns of pharmacological treatment and adherence among patients with bipolar disorder type I in the USA","volume":"14","author":"Greene","year":"2018","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"3","key":"10.1016\/j.jad.2019.06.050_bib0014","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jad.2011.10.033","article-title":"Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009","volume":"136","author":"Greil","year":"2012","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.jad.2019.06.050_bib0015","first-page":"87","article-title":"Compliance with maintenance treatment in bipolar disorder","volume":"33","author":"Keck","year":"1997","journal-title":"Psychopharmacol. Bull."},{"issue":"7","key":"10.1016\/j.jad.2019.06.050_bib0016","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/bdi.12013","article-title":"Lamotrigine as add-on treatment to lithium and divalproex: lessons learned from a double-blind, placebo-controlled trial in rapid-cycling bipolar disorder","volume":"14","author":"Kemp","year":"2012","journal-title":"Bipolar Disord."},{"issue":"6","key":"10.1016\/j.jad.2019.06.050_bib0017","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/archpsyc.62.6.617","article-title":"Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2019.06.050_bib0018","first-page":"543","article-title":"Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication","volume":"64","author":"Merikangas","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2019.06.050_bib0019","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1176\/appi.ajp.2012.12060751","article-title":"Lithium treatment moderate-dose use study (LiTMUS) for bipolar disorder: a randomized comparative effectiveness trial of optimized personalized treatment with and without lithium","volume":"170","author":"Nierenberg","year":"2013","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2019.06.050_bib0020","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4088\/JCP.14m09349","article-title":"Bipolar CHOICE (Clinical health outcomes initiative in comparative effectiveness): a pragmatic 6-month trial of lithium versus quetiapine for bipolar disorder","volume":"77","author":"Nierenberg","year":"2016","journal-title":"J. Clin. Psychiatry"},{"issue":"11","key":"10.1016\/j.jad.2019.06.050_bib0021","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/1740774513512184","article-title":"Clinical and health outcomes initiative in comparative effectiveness for bipolar disorder (bipolar CHOICE): a pragmatic trial of complex treatment for a complex disorder","volume":"11","author":"Nierenberg","year":"2014","journal-title":"Clin. Trials"},{"issue":"11","key":"10.1016\/j.jad.2019.06.050_bib0022","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/j.jpsychires.2013.07.009","article-title":"The medication recommendation tracking form: a novel tool for tracking changes in prescribed medication, clinical decision making, and use in comparative effectiveness research","volume":"47","author":"Reilly-Harrington","year":"2013","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2019.06.050_bib0023","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jad.2018.09.027","article-title":"Treatment effectiveness and tolerability outcomes that are most important to individuals with bipolar and unipolar depression","volume":"243","author":"Rosenblat","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2019.06.050_bib0024","first-page":"31","article-title":"Use of clonazepam for bipolar affective disorder","volume":"51","author":"Sachs","year":"1990","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2019.06.050_bib0025","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1176\/appi.ajp.159.7.1146","article-title":"Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety","volume":"159","author":"Sachs","year":"2002","journal-title":"Am. J. Psychiatry"},{"issue":"17","key":"10.1016\/j.jad.2019.06.050_bib0026","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa064135","article-title":"Effectiveness of adjunctive antidepressant treatment for bipolar disorder","volume":"356","author":"Sachs","year":"2007","journal-title":"NEJM"},{"key":"10.1016\/j.jad.2019.06.050_bib0027","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jad.2014.05.015","article-title":"Topiramate as an adjuvant treatment for obsessive compulsive symptoms in patients with bipolar disorder: a randomized double blind placebo controlled clinical trial","volume":"166","author":"Sahraian","year":"2014","journal-title":"J. Affect. Disord."},{"issue":"2","key":"10.1016\/j.jad.2019.06.050_bib0028","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.comppsych.2008.06.008","article-title":"Predictors of nonadherence among individuals with bipolar disorder receiving treatment in a community mental health clinic","volume":"50","author":"Sajatovic","year":"2009","journal-title":"Compr. Psychiatry"},{"key":"10.1016\/j.jad.2019.06.050_bib0029","doi-asserted-by":"crossref","first-page":"384","DOI":"10.4088\/JCP.v63n0502","article-title":"Nonadherence with mood stabilizaers: prevalence and predictors","volume":"63","author":"Scott","year":"2002","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2019.06.050_bib0030","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4088\/JCP.v58n0301","article-title":"A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I disorder","volume":"58","author":"Solomon","year":"1997","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2019.06.050_bib0031","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1192\/bjp.bp.107.041301","article-title":"Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes","volume":"192","author":"Tohen","year":"2008","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2019.06.050_bib0032","doi-asserted-by":"crossref","DOI":"10.1001\/archpsyc.59.1.62","article-title":"Efficacy of olanzapine in combination with valproate ro lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy","volume":"59","author":"Tohen","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2019.06.050_bib0033","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1192\/bjp.184.4.337","article-title":"Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone","volume":"184","author":"Tohen","year":"2004","journal-title":"Br. J. Psychiatry"},{"issue":"11","key":"10.1016\/j.jad.2019.06.050_bib0034","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.60.11.1079","article-title":"Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar i depression","volume":"60","author":"Tohen","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2019.06.050_bib0035","doi-asserted-by":"crossref","first-page":"223","DOI":"10.4088\/JCP.08m04152","article-title":"Efficacy and safety of lamotrigine as add-on treatment to LIthium in bipolar depression: a multicenter, double-blind, placebo-controlled trial","volume":"70","author":"van der Loos","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl. 4","key":"10.1016\/j.jad.2019.06.050_bib0036","first-page":"3","article-title":"The expert consensus guidelines series: adherence problems in patients with serious and persistent mental illness","volume":"70","author":"Velligan","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2019.06.050_bib0037","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jad.2008.06.001","article-title":"Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126)","volume":"109","author":"Vieta","year":"2008","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2019.06.050_bib0038","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1176\/appi.ajp.2014.13111501","article-title":"The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer","volume":"171","author":"Viktorin","year":"2014","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2019.06.050_bib0039","doi-asserted-by":"crossref","first-page":"5","DOI":"10.64719\/pb.4303","article-title":"Lamotrigine adjunctive therapy to lithium and divalproex in depressed patients with rapid cycling bipolar disorder and a recent substance use disorder: a 12 week, double-blind, placebo-controlled pilot study","volume":"43","author":"Wang","year":"2010","journal-title":"Psychopharmacol. Bull."},{"issue":"1","key":"10.1016\/j.jad.2019.06.050_bib0040","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.psychres.2014.01.038","article-title":"Medication burden in bipolar disorder: a chart review of patients at psychiatric hospital admission","volume":"216","author":"Weinstock","year":"2014","journal-title":"Psychiatry Res."},{"issue":"2","key":"10.1016\/j.jad.2019.06.050_bib0041","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00131746-200603000-00002","article-title":"Self-Rated global measure of the frequency, intensity, and burden of side effects","volume":"12","author":"Wisniewski","year":"2006","journal-title":"J. Psychiatr. Pract."},{"issue":"1\u20133","key":"10.1016\/j.jad.2019.06.050_bib0042","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jad.2006.08.017","article-title":"Pharmacological treatment of acute mania in psychiatric in-patients between 1994 and 2004","volume":"99","author":"Wolfsperger","year":"2007","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2019.06.050_bib0043","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1192\/bjp.182.2.141","article-title":"Mood stabilisers plus risperidone or placebo in the treatment of acute mania","volume":"182","author":"Yatham","year":"2003","journal-title":"Br J Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032719309644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032719309644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:17:58Z","timestamp":1777493878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032719309644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":43,"alternative-id":["S0165032719309644"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2019.06.050","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complex polypharmacy in bipolar disorder: Side effect burden, adherence, and response predictors","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2019.06.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}